Document is current
Any future updates will be listed below
-
Authors
Sasso, Ferdinando Carlo
Simeon, Vittorio
Galiero, Raffaele
Caturano, Alfredo
De Nicola, Luca
Chiodini, Paolo
Rinaldi, Luca
Salvatore, Teresa
Lettieri, Miriam
Nevola, Riccardo
Sardu, Celestino
Docimo, Giovanni
Loffredo, Giuseppe
Marfella, Raffaele
Adinolfi, Luigi Elio
Minutolo, Roberto
,
Amelia, U
Acierno, C
Calatola, P
Carbonara, O
Conte, G
Corigliano, G
Corigliano, M
D’Urso, R
De Matteo, A
De Nicola, L
De Rosa, N
Del Vecchio, E
Di Giovanni, G
Gatti, A
Gentile, S
Gesuè, L
Improta, L
LampitellaJr, A
Lampitella, A
Lanzilli, A
Lascar, N
Masi, S
Mattei, P
Mastrilli, V
Memoli, P
Minutolo, R
Nasti, R
Pagano, A
Pentangelo, M
Pisa, E
Rossi, E
Sasso, F C
Sorrentino, S
Torella, R
Troise, R
Trucillo, P
Turco, A A
Turco, S
Zibella, F
Zirpoli, L
- License Information
-
More Information
Article History
Received: 20 August 2022
Accepted: 24 October 2022
First Online: 7 November 2022
Declarations
:
: The trial was conducted in accordance with the guiding principles of the Declaration of Helsinki and was approved by the local ethics committee.
: Ferdinando Carlo Sasso has been member of Advisory Boards for Boehringer and for Ely-Lilly and has received fees for scientific consultation and/or lectures by Jansen, Roche Diagnostics, Novo Nordisk, Sanofi, MSD, Astrazeneca. Luca De Nicola has received fees for scientific consultation and/or lectures by Astellas, AstraZeneca, Mundibiopharma and Vifor Pharma. Roberto Minutolo has been member of Advisory Boards for Amgen, Astellas, Bayer and invited speaker at meetings supported by Amgen, Astellas, Vifor Pharma. Vittorio Simeon, Raffaele Galiero, Alfredo Caturano, Paolo Chiodini, Luca Rinaldi, Teresa Salvatore, Miriam Lettieri, Riccardo Nevola, Celestino Sardu, Giovanni Docimo, Giuseppe Loffredo, Raffaele Marfella and Luigi Elio Adinolfi have no conflict of interest to disclose.
